Drug therapies in older patients with glucocorticoid induced osteoporosis
Not Applicable
- Conditions
- glucocorticoid induced osteoporosis
- Registration Number
- JPRN-UMIN000015660
- Lead Sponsor
- Shimosizu Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
1. eGFR<35ml/min or Cre<1.5mg/ml 2. Past history of urinary tract stone 3. Hyper- or hypoparathyroidism 4. Hyper- or hypothyroidism 5. Contraindication of alendronate or vitamin D 6. Warfarinization 7. Other conditions that an investigator assess as inappropriate 8.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method proportions of symptomatic vertebral fracture
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways are targeted by therapies for glucocorticoid-induced osteoporosis in elderly patients?
How does the efficacy of JPRN-UMIN000015660 interventions compare to bisphosphonates or denosumab in GIOP management?
Which biomarkers correlate with treatment response in glucocorticoid-induced osteoporosis clinical trials?
What are the long-term safety risks of anti-osteoporotic drugs in older GIOP patients, and how are they mitigated?
What combination therapies are being explored alongside RANKL inhibitors for glucocorticoid-induced bone loss?